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Screening process
Our initial search identified 4,923 potentially eligible
studies (Figure 1). Teams of two reviewers
independently evaluated titles and, when available,
abstracts to determine whether or not the articles
might meet eligibility criteria. If either reviewer
concluded that there was any possibility that the article
would fulfill eligibility criteria, we obtained the full-text
publication.
Assessment of study eligibility
Research staff masked the results (blacked out the
results in tables and text) of all studies identified for
full evaluation in the screening process. Teams of two
reviewers independently assessed all studies identified
for full evaluation and resolved disagreements by
discussion. Reviewers never assessed the same report
at the title/abstract stage and at the full report stage.
For papers deemed eligible, two data abstractors
with access to the unmasked paper reviewed the
eligibility decision. If the data abstractors had
questions about eligibility, the pair of reviewers who
initially adjudicated the full blinded paper was
informed of the reason for the concern and, still blind
to results, reevaluated their initial decision. Their
decision after this second review was deemed final.
Methodological quality assessment and data abstraction
Teams of two reviewers independently assessed the
methods and abstracted data from all eligible studies;
they resolved disagreements through discussion.
Information relevant to the methodological quality of
the studies included the study design, the populations
selected (criteria for diagnosis, similarity of patient
groups in the two nations and the degree to which the
studied population was representative of the wider
universe of patients with the diagnosis), measurement
of outcome (that is, the extent to which the outcome
measures were defined similarly, and monitored
similarly), loss to follow-up, and the extent of risk
adjustment for confounders that might affect
prognosis. Other data we abstracted included the
geographic region in which the study was conducted,
the period of observation, the number of participants,
and the main outcomes.
We classified studies as being of high or low quality
according to the following two criteria:
For each study, two reviewers blinded to outcome
independently made the rating of high or low quality. If
we identified apparently contradictory decisions across
pairs of reviewers (for instance, if one set of reviewers
rated a study using Canadian and United States cancer
databases as high quality, and another team rated a
different study using the same databases as low
quality), we informed reviewers of the inconsistency.
The reviewers resolved the issue through discussion.
In response to editorial suggestions, we further
evaluated the issue of representativeness with more
rigorous and explicit criteria. We considered studies as
fully representative only if samples in both countries
were drawn from similar population-based registries
that included at least one entire Canadian province and
at least two entire American states, or a random
sample of patients from at least an entire province and
two entire American states.
For all eligible studies, we sent the original authors
our summary of the information abstracted from their
article and asked them to correct and complement as
they saw fit (11 authors, representing 16 studies,
responded). When authors provided additional specific
information or corrections, we incorporated these in
our descriptive tables. For two eligible abstracts,
4,5 we
requested and received a complete description of the
study from the authors.
Data analysis
When studies reported any outcome of importance
to patients (morbidity, mortality, or quality of life) but
did not state statistical significance, we calculated
associated p values using a threshold of 0.05 for
significance.
Because it was the most reliably and consistently
measured outcome, we restricted the meta-analyses to
the outcome of total mortality. When studies presented
outcome data at 1 and 6 months, we included data at 6
months, reasoning that if outcomes differ at 1 but not 6
months this is likely to be of limited importance to
patients.
The statistical analysis included each non-
overlapping study that provided the proportion of
patients who died either in Canada or the United
States, along with the associated variance (or data that
allowed its calculation). We pooled the results using a
random-effects model. We assess heterogeneity in
results using the Cochrane's Q test,
6 and calculated the
I
2.
7 Relative risk was used as the summary statistic.
When articles reported separate procedures (for
instance, mortality for different operations; mortality
for different cancers), we treated each patient
population as if it came from a separate study.
Similarly, if an article reported major sub-populations
within a patient group (such as low and high income),
we treated these groups as coming from separate
studies. We created funnel plots to provide graphical
evaluation of publication bias and used a statistical
technique suggested by Egger to provide a quantitative
evaluation of the likelihood of publication bias.
8
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from individual studies, we conducted meta-regression
analyses in which an additive between-study variance
component of residual heterogeneity was used in
accordance with the random effects. The dependent
variable was the log of the relative risk. The
independent variables were based on the following a
priori hypotheses explaining heterogeneity:
• overall study quality based on adequacy of
adjustment for potential confounders and
representativeness of the sample
• source of the data (primary data collection versus
administrative database)
• whether care was primarily out-patient or in-patient
• the extent to which US patients had health insurance
(in-hospital studies involving primarily those ≥65
years of age or any study undertaken in Veterans
Administration facilities will have excluded most
uninsured people)
• completeness of follow-up
• whether the US site included or was restricted to
New England (hypothesized to have better outcome
than in other areas of US)
9
• the underlying health problem (renal failure,
cardiology, cancer, surgery, and other)
• data collection before or after the median date of
1986 (we initially considered the key date for Canada
before or after all provinces entered into Medicare
[1970], and for the United States before or after the
introduction of Medicare and Medicaid [July 1,
1966]; this choice, however, would have led to
insufficient variability: almost all the data came from
after 1970).
Results
As presented in Figure 1, of the 4,923 titles and
abstracts identified, 498 appeared potentially eligible
on initial review, and 42 of these proved eligible on
review of the full article. We excluded three of these
publications because the data overlapped substantially
with those in another report that was eligible and
included.
10-12 One study was reported in two
complementary articles.
13,14
Table 1 summarizes the results in terms of high-
and low-quality studies, and whether results favoured
the United States, Canada, or showed mixed findings
or no difference. Table 2–Table 4 present key methods
and results beginning with the highest-quality studies
from population registries with adequate adjustment
(unshaded); then the intermediate quality studies that
were reasonably representative and had adequate
adjustment (lightly shaded); and finally the low-quality
studies in which the populations were unrepresentativeReview Guyatt et al
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or adjustment was inadequate (shaded).
Of the 5 studies that reported superior outcomes in
the United States, we classified 2 as high quality (one of
which utilized population registries) and 3 as low
quality (Table 2). Of the 2 high-quality studies, one
presents results from a population-based registry that
showed higher 30-day post-operative mortality after
hip fracture in Manitoba and Quebec in comparison to
several American states.
15 Canadians had longer wait
times for surgery, longer post-operative lengths of stay,
and higher inpatient mortality. Differences in mortality
were not, however, attributable to differences in wait
times for surgery. Furthermore, the increase in
mortality did not persist over time, and Canadian
outcomes proved superior for several other surgical
procedures
16,17 (Table 4).
The second high-quality study was prospectively
designed to examine outcomes of cataract surgery in a
number of countries, including Canada and the United
States.
13,14 The two reports of this study fail to describe
the mix of insured and uninsured patients in the US
sample.
The first of the low-quality studies favouring the US
presented results from administrative databases in the
United States and Ontario and showed similar survival
in patients with colon and lung cancer and Hodgkin’s
lymphoma, but superior survival in American breast
cancer patients.
18 Another study using the same
databases over a somewhat different (but overlapping)
period showed similar results for breast cancer and
Hodgkin’s disease, but found an overall survival
advantage for American patients in colon cancer and
Canadian patients in lung cancer
19 (Table 4). Two
studies that used the same database but restricted their
analysis to Toronto versus American cities that the
authors considered comparable showed a significant
advantage
20 or a trend
21 toward superior survival in
breast cancer patients in Canada versus the United
States (Table 3).
Other low-quality studies favouring the United
States include populations of patients with rheumatoid
arthritis and patients after myocardial infarction
(MI)
23. In the latter study looking at only one Canadian
and one US hospital, more aggressive treatment in the
United States was associated with superior functional
status, but not with any difference in recurrent MI or
death. Another much larger observational study also
found greater use of invasive treatments in the US with
superior functional status, but similar death and
reinfarction (though higher stroke) rates
24 (Table 4).
These results are not completely consistent across
studies. Indeed, one study that included 14 American
and 4 Canadian sites and over 2,000 patients
demonstrated similar rates of invasive procedures in
patients who experienced non-Q wave MI and unstable
angina, with a lower rate of recurrent ischemia in
hospital, at 6 weeks, and at 1 year in Canadian
patients
25 (Table 3). The finding of similar rates of
cardiovascular deaths in MI patients, with the
exception of slightly lower death rates in American
elderly patients in the first 3 months after MI,
26 does
appear consistent
27 (Table 4).
Of the 14 studies that demonstrated superior
outcomes in Canada, we classified 5 as high quality (3
from population-based registries, including all patients
from at least one Canadian province and two US states)
and 9 as low quality (Table 3). Five studies, two high
quality (one from a population-based registry) and
three low quality, showed consistently lower mortality
in Canadian than American patients with renal failure
(Table 3). These studies included administrative
database studies of black patients receiving renal
transplants,
28 of Manitoban and American patients
receiving either hemodialysis or peritoneal dialysis,
29
and of the entire Canadian and American populations
receiving peritoneal dialysis
30 or any dialysis.
4,31
Another study that almost certainly used similar data
sources but did not report their methods as thoroughly
also suggested lower mortality in Canadian than
American patients receiving dialysis or renal
transplants.
32 The strongest study from a data
collection and adjustment point of view (though with a
small number of American patients and not drawn
from a population-based registry), a prospective cohort
study in which the investigators were responsible for
data collection, showed lower mortality in Canadian
patients undergoing peritoneal dialysis.
33
The most rigorous of the dialysis studies, taking into
account both sampling and adjustment, used data from
5,192 patients in the US case-mix severity study (a
random sample of all Americans who began dialysis in
1986 or 1987). The investigators complemented these
data with clinical and administrative records from the
Henry Ford Hospital in Detroit, Michigan, and review
of charts of all patients (549) with end-stage renal
disease treated in the province of Manitoba between
1983 and 1989.
29 Case-mix adjustment included age,
sex, and a wide range of comorbidity (including
diabetes, coronary artery disease, heart failure,
respiratory disease, and cancer). After adjustment for
both case-mix and treatment variables (including
likelihood of transplant) the relative mortality rate was
47% higher in the US population (95% confidence
interval [CI] 16%–87%). One could argue that
treatment variables should not have been included in
the adjustment. If so, the increased risk of death in the
American population would have been even higher. By
far the biggest treatment-related variable that had an
impact on mortality was dialysis (relative mortality
0.53 in those transplanted). Transplantation rates were
35% in Manitoba and 17% in the American sample.
A series of reports used the National Cancer
Institute’s Surveillance, Epidemiology, and End Results
(SEER) and the Ontario Cancer Registry (OCR) toReview Guyatt et al
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compare cancer patients’ outcomes. Two of these
population-based studies also conducted chart reviews
in a sample of Canadian patients to obtain staging
information not available in the OCR database. These
investigations showed lower mortality rates in lower
stage supraglottic and glottic cancer in Canadian
patients, along with lower rates of laryngectomy.
34,35
The stronger of these studies, focusing on patients with
glottic cancer, supplemented electronic data from
population-based cancer registries with chart review,
hospital discharge data, and clinical databases and was
able to adjust for stage, age, and sex. Laryngectomy
rates across all stages were 5% in Canada and 13.9% in
the United States. Survival was similar in patients with
higher-stage disease, but Canadian patients with lower-
stage disease showed a statistically significant survival
advantage in years 2, 3, and 4.
The other studies utilizing these databases are
weaker because they do not adjust for cancer stage or
severity. One set of reports compared Toronto to a
number of American cities and suggested that poorer
Canadian patients fared better than their American
peers.
20,21,36 These results were only partly consistent
with a report from the entire SEER database and the
entire province of Ontario that supported the finding of
better outcomes in poorer Canadians than Americans,
but also suggested that wealthier Americans with
cancer may fare better than wealthier Canadians
19
(Table 4). Another study that used the same databases
and focused on head and neck cancer showed mixed
results
37 (Table 4). Other mixed findings from studies
using these databases are described earlier in the
Results.
18,19 Three smaller studies of cancer patients
that relied on chart review showed no differences in
outcomes between Canada and the United States
38-40
(Table 4).
A high-quality population-based study that looked
at the entire cystic fibrosis population in both countries
showed apparent benefits in height and weight from
Canadian care (Table 3). A second study restricted to
one Canadian and one US institution suggested higher
survival in Canadian cystic fibrosis patients.
42 A study
comparing AIDS patients in British Columbia to those
in a number of American cities suggested lower death
rates in Canadian patients; the only adjustment was for
baseline CD-4 count.
43
Of the 19 studies that demonstrated comparable or
mixed outcomes, we classified 3 as high quality (two
using population-based registries) and 16 as low quality
(Table 4). We have described some of these studies in
the context of studies included in Table 2 and Table 3.
High-quality studies relying on administrative
databases of broad populations have shown equivalent
mortality in Canada and the US in coronary artery
bypass grafting,
44 lower mortality in Canada in a variety
of low and moderate risk surgeries, and higher short
but not long-term mortality in high-risk surgeries,
including hip fracture repair.
16,17 Lower-quality studies
have suggested a similar incidence of low-birth-weight
infants,
45 no difference in outcomes in asthmatic
patients presenting to emergency departments,
5 no
difference in outcomes in critically ill patients
46 or
demented patients admitted to hospital,
47 and no
differences in functional status in patients with
rheumatoid arthritis.
48 A study that relied on volunteer
call-in found that Canadian women with nausea and
vomiting of pregnancy had more depression and more
adverse effects on marital relationships, but fewer lost
hours of paid work, less hospitalization, and less weight
loss than did American women suffering from the
condition.
49 A study that relied on an administrative
database from one US and one Canadian hospital
found higher intensive care unit (ICU) admission rates
and longer ICU stays, but shorter overall hospital stays,
in US patients hospitalized for trauma.
50
Statistical Analysis
The statistical analysis was based on results of 83
populations in 23 studies that reported all-cause
mortality with sufficient completeness for inclusion.
15-
18,20-23,25-27,29,33,37-40,42,43,46,47,50 In Figure 2, which depicts
the distribution of the log of the relative risk against
the precision of the estimates (the inverse of the
standard deviation of the log RR), values to the left of 0
favour Canada and values to the right of 0 favour the
United States. The pooled relative risk of dying in
Canada versus the United States was 0.95 (95% CI 0.92
to 0.98, p = 0.002, heterogeneity p < 0.0001, I
2 =
0.94). The plot suggests some asymmetry, with a
number of low-precision studies favouring Canada
without corresponding studies favouring the United
States. This is consistent with the statistical analysis,
which suggested rejecting the null hypothesis of no
asymmetry (p = 0.02). One possible explanation for
this result is publication bias in Canada’s favour.
Table 5 presents the results of the univariable and
multivariable regressions. The results show no
variables as significant in the univariable model,
whereas several are significant in the multivariable
model: study quality (higher-quality studies tend to
favour the US); whether New England was included
(inclusion of New England tends to an estimate of
lower mortality in Canada); and disease category (renal
failure, cancer, and surgery tended to favour Canada;
cardiology and other studies tended to favour the US).
Neither the univariate models, nor the multivariate
model (despite apparently explaining 49% of the
variance) were stable. For instance, omission of two
relatively large studies that represented outliers
resulted in very different results.Review Guyatt et al
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Discussion
In this systematic review, we demonstrated that
although Canadian outcomes were more often superior
to US outcomes than the reverse, neither the United
States nor Canada can claim hegemony in terms of
quality of medical care and the resultant patient-
important outcomes. In virtually all areas, study results
have demonstrated some apparent advantages for
Canada and others for the United States. In cancer,
where a number of strong studies have used population-
based registries, Canadian outcomes appear superior in
head and neck cancer, and possibly for low-income
patients with a variety of cancers; American women
with breast cancer appear to have better survival rates
than Canadian women. In data from population-based
registries, Canadians enjoy better risk-adjusted survival
after a variety of surgeries, but American outcomes
appear superior after hip fracture repair and cataract
surgery. Studies that do not utilize population-based
registries suggest that Americans have, possibly as a
result of more aggressive interventions, less angina
after MI, but the benefit may come at the price of
increased strokes and bleeding. There is one area in
which Canadian outcomes appear consistently
superior: end-stage renal failure. Even here, however,
as we shall discuss, one cannot be certain that superior
medical care is responsible for the differences.
The strengths and limitations of this systematic
review bear on its interpretation. We established a
team that included expertise in medicine, clinical
epidemiology, health economics, health policy, and
health services research in both Canada and the United
States, developed explicit eligibility criteria, and
conducted a comprehensive search that uncovered a
number of eligible articles not included in a previous
systematic review.
51 We excluded studies, such as
randomized trials of medical interventions in which
Canadian investigators recruited some patients and
American investigators others, in which care would be
idiosyncratic or atypical of care in usual clinical
practice. Our thorough examination of each study
addressed issues of validity (selection of populations,
adjustment for confounders, loss to follow-up) and
generalizability (breadth of samples, including
specifying studies that came from population-based
registries).
Reviewers who determined eligibility and judged
validity and generalizability were blind to the results of
the study. In decision-making regarding methodologic
issues that arose as the review progressed, we recused
investigators who were aware of the study results. We
made explicit a priori hypotheses regarding possible
sources of heterogeneity, and tested these hypotheses
in a thorough statistical analysis. Our results are
consistent with those of a prior systematic review that
completed its search (less comprehensive than ours) in
1997, conducted a limited assessment of study validity,
and failed to conduct a formal meta-analysis.
51
The main limitation of our review is in the uneven
quality of the original studies, and the threats to
validity that remain even in those studies of high
quality. There were two key ways a study could fail to
adequately address our question: either the population
might be small or narrow, or the investigators might
not carry out statistical adjustment for potential
differences in underlying prognosis. Most of the studies
we identified failed one of these two criteria (Tables 2-
4).
Even studies that meet these criteria, and meet the
more rigorous criterion of utilizing population-based
registries, present challenges with respect to their
interpretation. In general, a health care system can
improve outcomes in two ways. One is to facilitate early
entry to care, including preventive care, and thus avoid
unnecessary morbidity and mortality. For instance, if
access to primary care is easy and without financial
obstacles, one might expect superior outcomes in
hypertension (e.g., fewer strokes). Alternatively, a
system might generate better outcomes by better
treatment of serious morbidity once it arises. For
instance, stroke patients may be more likely to receive
early thrombolysis, thromboprophylaxis, and
multidisciplinary rehabilitation.
If a health system does better in early identification
and treatment, diseased patients in that system will
appear less ill. Statistical adjustment for severity of
illness is in general appropriate – one wouldn’t want to
attribute to better care what is in fact due to a better
prognosis. The risk, however, is that the adjustment
will obscure the benefits of early identification and
treatment.
Such issues become relevant in comparisons of
outcomes between Canada and the United States. For
instance, the United States does a better job of
screening women for breast cancer.
52 To the extent that
early diagnosis reduces breast cancer deaths, one
would expect a survival advantage for American
women. At the same time, any apparent increase inReview Guyatt et al
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longevity may be largely, or even completely, due to the
length and lead-time biases inherent in observational
studies of screening.
A number of studies using the American National
Cancer Institute’s Surveillance, Epidemiology, and End
Results Program (SEER) and the Ontario Cancer
Registry (OCR) have addressed breast cancer
outcomes. Although studies using these databases and
examining Toronto versus a number of US cities
suggest higher breast cancer survival in low-income
Canadian women than in their American
counterparts,
20,21,36 several studies using the entire
database have suggested superior overall breast cancer
survival in American women.
18,19,32 We rated these
studies as low quality because of failure to adjust for
disease stage. If higher screening rates or better self-
detection in the US result in the identification of earlier
stage histologic cancers that would have remained
asymptomatic and dormant, studies would
demonstrate superior survival despite equivalent
medical care. On the other hand, perhaps there is a true
American advantage that results from higher rates of
screening
52 or from superior care after diagnosis. The
data do not allow assessment of the relative likelihood
of these possible explanations.
These studies raise another important limitation of
the current data. Canada has largely
53 (though not
completely) eliminated gradients in access to care by
socioeconomic status that remain in the United
States,
55,56 and this may contribute to Canada’s smaller
socioeconomic gradients in health outcome.
57 If this
were so, one would expect that studies focused on
poorer individuals would reveal superior outcomes in
Canada, whereas differences might be obscured in
studies of entire populations. Indeed, the cancer
studies by Gorey and colleagues
20,21,36 and by Boyd
19
suggest this may be the case. At the same time, it is
possible that being able to pay for better care might
lead to better outcomes in those with high incomes in
the US versus Canada. Indeed one of the studies in
cancer patients suggested this possibility.
19
Unfortunately, these are the only studies that explore
gradients in outcome across socioeconomic status.
Although the overall effect in the meta-analysis may
be of some interest (a 5% reduction in relative risk of
all-cause mortality in Canada versus the United States)
the large variability in study results (heterogeneity p <
0.0001, I
2 94%, Figure 2) makes the pooled estimate
difficult to interpret. Our primary reason for
conducting the statistical analysis was, through meta-
regression, to explore possible explanations of
variability in results and provide adjusted estimates of
relative risk. This exploration proved difficult to
interpret. Although the multivariate model identified
apparent sources of heterogeneity and provided
adjusted estimates of relative risk (Table 5), the results
were inconsistent between univariate and multivariate
approaches, and both the univariable and multivariable
models were very unstable. Thus, we do not feel
confident that the statistical modeling has provided
either a satisfactory explanation for the study-to-study
variability in results or credible estimates of adjusted
relative risk.
One group of patients fared consistently better in
Canada than in the U.S., those with end-stage renal
disease.
4,28-33 Whether in hemodialysis programs,
peritoneal dialysis, or after receipt of renal transplants,
Canadians survive longer. The larger proportion of
Americans than Canadians who begin dialysis
treatment confounds interpretation of this finding.
Perhaps Americans fare worse because a larger number
of sicker patients enter dialysis. On the other hand, it
may be that the larger proportion of Americans on
dialysis reflects a lower threshold to start dialysis, and
thus a less sick dialysis population. The limited
available evidence suggests that thresholds for dialysis
are in fact similar in the two countries.
58 Furthermore,
two high-quality studies that included extensive
adjustment for comorbidity
29,33 still show substantially
lower mortality in Canadian patients, suggesting that
imbalance in risk cannot explain superior Canadian
outcomes.
Nevertheless, the weight of the evidence strongly
suggests that Canadian end-stage renal patients truly
have higher survival than those in the US. The
explanation for this difference may lie in differences in
the ownership of dialysis facilities. Virtually all
Canadian dialysis care is not-for-profit, while for-profit
providers deliver approximately 75% of American care
for end-stage renal failure. A systematic review has
shown a higher mortality in patients undergoing
dialysis in for-profit centres.
59
Despite the limitations of the available studies,
some robust conclusions are possible from our
systematic review. These results are incompatible with
the hypothesis that American patients receive
consistently better care than Canadians. Americans are
not, therefore, getting value for money; the 89% higher
per-capita expenditures on health care in the United
States does not buy superior outcomes for the sick.
Canadian health care has many well-publicized
limitations. Nevertheless, it produces health benefits
similar, or perhaps superior, to those of the US health
system, but at a much lower cost. Canada’s single-
payer system for physician and hospital care yields
large administrative efficiencies in comparison with the
American multi-payer model.
60 Not-for-profit hospital
funding results in appreciably lower payments to third-
party payers in comparison to for-profit hospitals61
while achieving lower mortality rates.
62 Policy debates
and decisions regarding the direction of health care in
both Canada and the United States should consider the
results of our systematic review: Canada’s single-payer
system, which relies on not-for-profit delivery, achieves
health outcomes that are at least equal to those in the
United States at two-thirds the cost.Review Guyatt et al
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